Background

Gene delivery techniques aimed at treating central nervous system (CNS) diseases have long been a goal in the medical field. However, drugs targeting the brain invariably encounter the formidable blood-brain barrier (BBB). This barrier, which prevents the entry of foreign substances, makes it nearly impossible for therapeutic genes to penetrate deep into the brain. Systemic administration, which involves directly injecting gene delivery vectors into the bloodstream, also has limitations, as only a minimal amount of the drug reaches the brain. Simply increasing the drug dosage risks accumulating in other organs, such as the liver or kidneys, potentially leading to off-target toxicity.

Furthermore, even if the drug is successfully delivered into the brain tissue, selectively introducing genes into specific cells is challenging. Glial cells, which support neurons and maintain brain homeostasis, are implicated in the pathogenesis of various genetic disorders. A technique that can target these cells and uniformly deliver therapeutic genes over a wide area has been lacking. Existing local injection methods have the drawback of confining the drug to the narrow area where the needle is inserted, preventing it from spreading to the broader brain regions. Therefore, there is an urgent need for a new delivery method that can precisely target glial cells throughout the brain while minimizing systemic side effects.

Key Findings

A research team led by Professors Steven A. Goldman and Maiken Nedergaard at the University of Rochester Medical Center overcame these two challenges by developing a combined gene delivery platform. In their study, they utilized a special chimeric mouse model in which human glial progenitor cells (hGPCs) were transplanted, allowing human brain cells to grow. They injected a library of adeno-associated virus (AAV) serotype 5-based capsids into the brain of this model and screened for viruses that specifically bind to and replicate in hGPCs. In vivo screening successfully identified an optimal capsid variant with high binding affinity to human glial cells expressing Cre-recombinase driven by the PDGFRA promoter.

The research team further enhanced the delivery efficiency of the targeted AAV variant by focusing on the glymphatic system, the brain's natural circulatory system. They first injected the drug into the intracisternal space, where cerebrospinal fluid (CSF) flows directly. Simultaneously, they induced a systemic hypertonicity by increasing the concentration of solutes in the blood. This osmotic change draws fluid into the brain tissue, dramatically accelerating the flow of CSF into the perivascular space. The AAV variant, carried by this passive flow, bypassed the BBB and spread smoothly throughout the brain cortex. The leakage of the virus into major organs, including the liver, was blocked, while the efficiency of glial cell delivery in the brain was significantly higher than that of AAV5.

Significance and Prospects

This study is considered a breakthrough because it provides a tool for genetically reprogramming glial cells distributed throughout the brain. It opens the door to immediate applications in treating diseases such as multiple sclerosis (MS), a demyelinating disease, and Huntington's disease, a neurodegenerative disorder. A concrete roadmap for clinical trials has been established, involving the delivery of gene scissors that either repair abnormal glial cells or eliminate mutated genes. The glymphatic stimulation method, which regulates brain pressure to activate the brain's natural cleansing pathways, is expected to become a universal method for enhancing gene therapy efficiency.

However, there are still hurdles to overcome before this can be applied to actual patients. The method of inducing systemic hypertonicity by administering mannitol needs to be rigorously tested to ensure its physiological safety in human patients. Furthermore, the brain volume and the structural scale of the perivascular space are significantly different between chimeric mice and humans. Therefore, follow-up studies should be conducted to confirm whether gene delivery via the glymphatic flow occurs uniformly in larger animal models, such as primates. If these limitations can be addressed, this technique is expected to become the most sophisticated and safe treatment method in the field of CNS drug delivery.